NetworkNewsBreaks – TC BioPharm Holdings PLC (NA
Post# of 10
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. According to the announcement, Bryan Kobel, CEO of TC BioPharm, will deliver a presentation providing an overview of the company’s business.
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://nnw.fm/TCBP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer